ALB and neoplasm: Although albumin binders are generally designed to delay blood clearance, thereby increasing tumor accumulation and reducing renal uptake, some recent reports have emphasized that the actual pharmacokinetic profile depends heavily on binder affinity, molecular linkage, and isotope half-life.